Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999818 | 0.87 | ACLY (0.53) | ACLYTRPV4ABL1SERPINH1CDK1 | |
| SCHEMBL4468249 | 0.85 | ACLY (0.51) | ACLYTRPV4ABL1SERPINH1PDK2 | |
| SCHEMBL17078006 | 0.83 | TRPV4 (0.56) | ACLYTRPV4ABL1CDK1SLC6A4 | |
| SCHEMBL21046732 | 0.83 | CA1 (0.47) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL5452555 | 0.80 | ABL1 (0.58) | ACLYTRPV4ABL1PDK2SLC6A4 | |
| SCHEMBL24457823 | 0.80 | WDR5 (0.43) | TRPV4 | |
| SCHEMBL19682407 | 0.77 | ABL1 (0.42) | ACLYABL1SERPINH1PDK2SLC6A4 | |
| SCHEMBL3530326 | 0.77 | CA1 (0.54) | TRPV4CDK1PDK2SLC6A4SLC6A3 | |
| SCHEMBL21798603 | 0.76 | GAA (0.46) | TRPV4ABL1CDK1CA1CA2 | |
| SCHEMBL15390723 | 0.75 | ABL1 (0.47) | ABL1SERPINH1PDK2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2024249493-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-11-14 | — | — | US | disclosed |
| EP-4440703-A1 | HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| EP-4247795-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023102228-A1 | HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102228-A1 | HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220274934-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2022-09-01 | — | — | US | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | ACLY 3280/4885TRPV4 4568/4885ABL1 786/4885 |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ACLY 3526/4885TRPV4 4296/4885ABL1 786/4885 |
| US-20220274934-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ACLY 3526/4885TRPV4 4296/4885ABL1 786/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ACLY 3526/4885TRPV4 4296/4885ABL1 786/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | ACLY 3542/4885TRPV4 4119/4885ABL1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.